SG11202102875YA - Anti-fgfr2 antibody formulations - Google Patents
Anti-fgfr2 antibody formulationsInfo
- Publication number
- SG11202102875YA SG11202102875YA SG11202102875YA SG11202102875YA SG11202102875YA SG 11202102875Y A SG11202102875Y A SG 11202102875YA SG 11202102875Y A SG11202102875Y A SG 11202102875YA SG 11202102875Y A SG11202102875Y A SG 11202102875YA SG 11202102875Y A SG11202102875Y A SG 11202102875YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody formulations
- fgfr2 antibody
- fgfr2
- formulations
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862741772P | 2018-10-05 | 2018-10-05 | |
PCT/US2019/054684 WO2020072896A1 (en) | 2018-10-05 | 2019-10-04 | Anti-fgfr2 antibody formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102875YA true SG11202102875YA (en) | 2021-04-29 |
Family
ID=68343457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102875YA SG11202102875YA (en) | 2018-10-05 | 2019-10-04 | Anti-fgfr2 antibody formulations |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220010020A1 (ru) |
EP (1) | EP3860563A1 (ru) |
JP (1) | JP2022503886A (ru) |
KR (1) | KR20210074286A (ru) |
CN (1) | CN112804989A (ru) |
AU (1) | AU2019355995A1 (ru) |
BR (1) | BR112021005204A2 (ru) |
CA (1) | CA3112215A1 (ru) |
CO (1) | CO2021004985A2 (ru) |
CR (1) | CR20210217A (ru) |
EA (1) | EA202190878A1 (ru) |
EC (1) | ECSP21031139A (ru) |
IL (1) | IL281976A (ru) |
MX (1) | MX2021003766A (ru) |
PE (1) | PE20211213A1 (ru) |
PH (1) | PH12021550670A1 (ru) |
SG (1) | SG11202102875YA (ru) |
WO (1) | WO2020072896A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
EP4273166A1 (en) * | 2020-12-29 | 2023-11-08 | Shenzhen Forward Pharmaceuticals Co., Limited | Anti-fgfr2 antibody and use thereof |
TW202342527A (zh) * | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
WO2023185778A1 (en) * | 2022-03-28 | 2023-10-05 | Genor Biopharma Co., Ltd. | Novel anti-fgfr2 antibodies |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
JP5071942B2 (ja) | 2007-01-24 | 2012-11-14 | 協和発酵キリン株式会社 | エフェクター活性が増強された遺伝子組換え抗体組成物 |
NO2842573T3 (ru) | 2008-11-07 | 2018-02-24 | ||
HUE043815T2 (hu) | 2013-08-01 | 2019-09-30 | Five Prime Therapeutics Inc | Fukózmentes FGFR2IIIB elleni antitestek |
TWI791422B (zh) | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
-
2019
- 2019-10-04 JP JP2021517575A patent/JP2022503886A/ja active Pending
- 2019-10-04 SG SG11202102875YA patent/SG11202102875YA/en unknown
- 2019-10-04 CN CN201980064961.XA patent/CN112804989A/zh active Pending
- 2019-10-04 PE PE2021000414A patent/PE20211213A1/es unknown
- 2019-10-04 EP EP19794304.6A patent/EP3860563A1/en active Pending
- 2019-10-04 CR CR20210217A patent/CR20210217A/es unknown
- 2019-10-04 AU AU2019355995A patent/AU2019355995A1/en active Pending
- 2019-10-04 US US17/282,589 patent/US20220010020A1/en active Pending
- 2019-10-04 CA CA3112215A patent/CA3112215A1/en active Pending
- 2019-10-04 EA EA202190878A patent/EA202190878A1/ru unknown
- 2019-10-04 BR BR112021005204-6A patent/BR112021005204A2/pt unknown
- 2019-10-04 MX MX2021003766A patent/MX2021003766A/es unknown
- 2019-10-04 KR KR1020217009515A patent/KR20210074286A/ko active Search and Examination
- 2019-10-04 WO PCT/US2019/054684 patent/WO2020072896A1/en active Application Filing
-
2021
- 2021-03-25 PH PH12021550670A patent/PH12021550670A1/en unknown
- 2021-04-01 IL IL281976A patent/IL281976A/en unknown
- 2021-04-19 CO CONC2021/0004985A patent/CO2021004985A2/es unknown
- 2021-05-03 EC ECSENADI202131139A patent/ECSP21031139A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12021550670A1 (en) | 2022-01-03 |
ECSP21031139A (es) | 2021-06-30 |
EP3860563A1 (en) | 2021-08-11 |
JP2022503886A (ja) | 2022-01-12 |
EA202190878A1 (ru) | 2021-07-02 |
KR20210074286A (ko) | 2021-06-21 |
US20220010020A1 (en) | 2022-01-13 |
BR112021005204A2 (pt) | 2021-06-08 |
CR20210217A (es) | 2021-06-18 |
WO2020072896A1 (en) | 2020-04-09 |
CO2021004985A2 (es) | 2021-04-30 |
PE20211213A1 (es) | 2021-07-05 |
CA3112215A1 (en) | 2020-04-09 |
CN112804989A (zh) | 2021-05-14 |
IL281976A (en) | 2021-05-31 |
AU2019355995A1 (en) | 2021-04-08 |
MX2021003766A (es) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279321A (en) | Anti-SIRPalpha antibody | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL280780A (en) | Anti-TIGIT antibodies | |
IL279352A (en) | IL-11RA antibodies | |
IL280013A (en) | Anti-IL36R antibodies | |
IL278010A (en) | Antibodies to galectin 10 | |
IL264502B1 (en) | Anti-cd3 antibody formulations | |
IL276626A (en) | Formulations of B7-H4 antibody | |
IL286100A (en) | Formulations of anti-il-36r antibodies | |
IL277030A (en) | Antibodies | |
IL281717A (en) | Antibody formulation | |
GB202110263D0 (en) | Anti-btla antibodies | |
ZA202101177B (en) | Anti-btla antibody | |
IL281976A (en) | Formulations of anti-FGFR2 antibody | |
IL282813A (en) | Formulation of antibodies | |
GB201811368D0 (en) | Antibody | |
IL291131A (en) | Formulations of anti-il-23p19 antibodies | |
IL281594A (en) | Antibodies against KLRG1 | |
GB201817172D0 (en) | Antibody | |
IL283886A (en) | Antibody Formulations | |
GB201806084D0 (en) | Antibodies | |
ZA202006263B (en) | Antibody formulation | |
ZA202006262B (en) | Stable antibody formulation | |
SG11202011823SA (en) | Activator-nucleator formulations | |
GB201813597D0 (en) | Antibody |